Document is current
Any future updates will be listed below
-
Authors
Guan, Yuting https://orcid.org/0000-0003-1866-270X
Liang, Xiujie
Ma, Ziyuan https://orcid.org/0000-0002-1512-8993
Hu, Hailong
Liu, Hongbo https://orcid.org/0000-0002-0733-8616
Miao, Zhen https://orcid.org/0000-0002-3255-9517
Linkermann, Andreas https://orcid.org/0000-0001-6287-9725
Hellwege, Jacklyn N. https://orcid.org/0000-0001-7479-0920
Voight, Benjamin F. https://orcid.org/0000-0002-6205-9994
Susztak, Katalin https://orcid.org/0000-0002-1005-3726
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK076077, R01 DK087635)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
- License Information
-
More Information
Article History
Received: 19 December 2020
Accepted: 3 August 2021
First Online: 23 August 2021
Competing interests
: The Susztak lab is supported by Boehringer Ingelheim, Regeneron, Bayer, GSK, Merck, and Novo Nordisk for work unrelated to the current manuscript. A.L. issued a patent for a combined necroptosis/ferroptosis inhibitor with the number 20160943.5. K.S. serves on the advisory board of Jnana therapeutics. The remaining authors declare no competing interests.
